Beta Bionics, Inc. Common Stock (BBNX) - Total Liabilities
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has total liabilities worth $36.02 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BBNX long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Beta Bionics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Beta Bionics, Inc. Common Stock total assets.
Beta Bionics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
China | CN¥678.48 Million |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥915.74 Million |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
India | Rs1.21 Billion |
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
China | CN¥1.50 Billion |
|
LIGHTHOUSE PROPERTIES
F:87O
|
Germany | €738.44 Million |
|
Cryoport Inc
NASDAQ:CYRX
|
USA | $265.50 Million |
|
Renta 4 Banco S.A
MC:R4
|
Spain | €2.43 Billion |
|
Metro Healthcare Indonesia
JK:CARE
|
Indonesia | Rp1.17 Trillion |
Liability Composition Analysis (2022–2025)
This chart breaks down Beta Bionics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BBNX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beta Bionics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $41.13 Million | -44.14% |
| 2024-12-31 | $73.63 Million | +43.16% |
| 2023-12-31 | $51.43 Million | -74.98% |
| 2022-12-31 | $205.56 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more